India Generics Makers Fear MNC Pact With Interpol To Stop Counterfeits
This article was originally published in PharmAsia News
Executive Summary
India's makers of generic drugs are concerned shipments of their products abroad could encounter difficulties due to a new pact between Interpol and a group of 29 global pharmaceutical companies, including Pfizer and GlaxoSmithKline.